// Learn · Regulation

What Actually Changes If 7-OH Is Scheduled on August 5

August 5, 2026 is the earliest date the DEA could make a temporary Schedule I order for 7-hydroxymitragynine effective. It is not a deadline, and it is not a certainty. Here is what an order would actually change — and what it wouldn't — answered question by question, without the panic framing.

When could an order take effect?

The DEA is using the temporary scheduling pathway under 21 U.S.C. § 811(h), the same mechanism it has used for synthetic cannabinoids and fentanyl analogs. The sequence is fixed by statute: the agency publishes a notice of intent, waits at least 30 days, and may then issue a final order. That order takes effect the day it publishes in the Federal Register — not 30 or 60 days later.

The notices published in the Federal Register on July 6, 2026, which puts the earliest possible effective date at August 5, 2026. In practice, temporary orders have often landed weeks or months after the earliest legal date, and the agency can also decline to act at all. Watch the Federal Register, not vendor countdown clocks.

Which products fall above the line?

A temporary order would list 7-hydroxymitragynine itself as a Schedule I substance. The products squarely covered are the ones built around concentrated or added 7-OH:

• 7-OH tablets — the dominant format, typically 15–30 mg of 7-OH per tablet, sold as singles at convenience counters for roughly $8–15 and in 10- to 50-count multipacks that bring per-tablet cost down to about $6–8.
• 7-OH gummies and chewables with declared 7-OH content per piece.
• Liquid shots and drink mixes where 7-OH is the labeled active alkaloid.
• Isolate and bulk powder sold by 7-OH percentage — anything with a COA showing purified or enriched 7-OH.

On the effective date, these become federally illegal to manufacture, distribute, or sell. There is no grandfathering: warehouse and shelf inventory of a covered product cannot lawfully be sold through unless the order itself carves out a wind-down period, which temporary orders historically have not done.

What falls below it — and stays legal?

Dried kratom leaf naturally contains only trace amounts of 7-OH — commonly cited figures run well under 0.05 percent of dry-leaf weight, versus mitragynine at roughly 1–2 percent. An order aimed at concentrated 7-OH is not expected to reach plain leaf powder, crushed leaf, or leaf capsules, and no federal proposal to date has targeted mitragynine itself.

That leaves a fairly clear picture of what remains federally lawful:

• Traditional kratom leaf powder and leaf capsules with no added alkaloids.
• Mitragynine-based extracts and tablets that contain no enriched or added 7-OH.
• Non-kratom botanicals entirely outside the order.

Two caveats. First, the final order's exact language controls — if it sets a quantitative threshold for naturally occurring 7-OH, that number decides edge cases like strong full-spectrum extracts. Second, federal legality is only half the map: kratom in any form is already banned in Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin, and 7-OH specifically stopped shipping to Tennessee and Kansas on July 1, 2026. Mississippi allows 7-OH for adults 21+ except in 11 northeastern counties. Favor'd Alkz keeps a current category-by-category breakdown of what stays legal in 2026 that is worth bookmarking alongside the federal docket.

How long does temporary scheduling last?

Two years from the effective date, extendable once by up to one additional year — a maximum of three years total. The extension exists to buy time for permanent scheduling, which is a separate, slower process: HHS conducts a scientific and medical evaluation, the DEA weighs the statutory eight-factor analysis, and a full notice-and-comment rulemaking follows. Permanent scheduling can also conclude with a lower schedule or no scheduling at all. In other words, an August order would set the rules into 2028, not forever.

What should buyers watch for from vendors?

The weeks around an effective date are when marketing gets loudest and least reliable. A few concrete signals separate vendors handling this properly from those improvising:

• A dated compliance statement that cites the actual order, not vague "fully legal" badges.
• ISO 17025 lab reports that quantify 7-OH, not just mitragynine — the only way to verify a "threshold-compliant" claim is a number on a COA.
• Reformulated product lines announced before the deadline, with new COAs, rather than the same SKUs quietly relabeled.
• Clear order-cutoff and refund policies for anything unshipped on the effective date.

For a buyer's-eye view of how the major vendors are positioning their catalogs — what will actually still be purchasable and from whom — 7ohBlack's rundown of what buyers can realistically get after August 5 is the most specific treatment we've seen.

Read "legal alternative" claims skeptically

Expect a wave of products marketed as drop-in 7-OH replacements. Some will be legitimate — traditional leaf and clean mitragynine products genuinely sit outside a 7-OH order. Others are already inside the federal action: mitragynine pseudoindoxyl, MGM-15, and MGM-16 are named in the DEA's companion scheduling notice, so a "pseudo" or MGM product is not a loophole at all. And for truly novel compounds invented after the fact, the Federal Analogue Act (21 U.S.C. § 813) lets prosecutors treat a substance "substantially similar" to a Schedule I compound, intended for human consumption, as if it were scheduled. A product invented specifically to skirt a fresh order is exactly the profile that statute was written for. The safer evaluation habit is simple: ask what the compound is, ask for the COA that quantifies it, and check whether the vendor's legal claim cites anything more specific than its own marketing.

Frequently asked questions